Asset
ADEFOVIR DIPIVOXIL
Gilead Sciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00002161 | — | completed | — | — | Gilead Sciences | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3 |
| NCT00002184 | phase2 | completed | — | — | Gilead Sciences | A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient |
| NCT00002206 | phase1 | completed | — | — | Gilead Sciences | A Study of Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Been Treated With Anti-HIV Drugs |
| NCT00002426 | — | completed | — | — | Gilead Sciences | A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients |
| NCT00158704 | — | terminated | 2002-01-01 | — | Gilead Sciences | Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection. |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 021449 | NDA | GILEAD SCIENCES INC |
Marketed products (1)
- HEPSERA